Straits Times Index
3,415.51 +47.61 (+1.41%) Nikkei
40,751.51 +170.75 (+0.42%) Hang Seng
17,978.57 +209.47 (+1.18%) FTSE 100
8,171.12 +49.92 (+0.61%) Bitcoin USD
60,359.98 -1,660.75 (-2.68%) CMC Crypto 200
1,264.31 -70.60 (-5.29%)
Daiichi Sankyo Company, Limited (4568.T)
| Previous close | 5,675.00 |
| Open | 5,684.00 |
| Bid | 5,617.00 x N/A |
| Ask | 5,615.00 x N/A |
| Day's range | 5,608.00 - 5,718.00 |
| 52-week range | 3,566.00 - 5,848.00 |
| Volume | |
| Avg. volume | 4,350,491 |
| Market cap | 10.734T |
| Beta (5Y monthly) | 0.25 |
| PE ratio (TTM) | 53.76 |
| EPS (TTM) | 104.42 |
| Earnings date | 29 Jul 2024 - 02 Aug 2024 |
| Forward dividend & yield | 60.00 (1.06%) |
| Ex-dividend date | 27 Sept 2024 |
| 1y target est | 6,180.80 |
- Business Wire
Arbitration Dispute Between Daiichi Sankyo and Seagen Ends
TOKYO & BASKING RIDGE, N.J., June 28, 2024--A dispute between Daiichi Sankyo Co., Ltd. (TSE: 4568) and Seagen Inc. is now concluded and Seagen has paid Daiichi Sankyo approximately U.S. $47 million in connection with attorneys’ fees and costs plus interest awarded by the arbitrator of the party’s dispute.
ZacksMerck's (MRK) Lung Cancer Candidate Faces FDA Rejection
The FDA's CRL to Merck (MRK) and its partner Daiichi Sankyo for the patritumab deruxtecan BLA is based on observations made on inspection of a third-party manufacturing facility.
BenzingaFDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug
On Wednesday, the FDA issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) seeking accelerated approval of Daiichi Sankyo (OTC:DSKYF) (OTC:DSNKY) and Merck & Co Inc’s (NYSE:MRK) patritumab deruxtecan (HER3-DXd) for adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies. The CRL results from findings about an inspection of a third-party manufacturing facility. The CRL
